• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@GOP
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • WoS İndeksli Yayınlar Koleksiyonu
  • View Item
  •   DSpace@GOP
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • WoS İndeksli Yayınlar Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

An overview of procalcitonin in Crimean-Congo hemorrhagic fever: clinical diagnosis, follow-up, prognosis and survival rates

Access

info:eu-repo/semantics/closedAccess

Date

2020

Author

Ekici-Gunay, Nahide
Koyuncu, Serhat

Metadata

Show full item record

Abstract

Objectives: This study investigates whether a diagnostic threshold value of procalcitonin exists in Crimean-Congo hemorrhagic fever (CCHF), while also determining the correlation between serum procalcitonin and routine diagnostic laboratory markers, monitoring changes in procalcitonin levels over time during hospitalization, and exploring the effect of procalcitonin levels on survival rates. Methods: A total of 161 patients, including 100 with laboratory-confirmed diagnosis of CCHF and 61 as a control group, were retrospectively investigated. Receiver operating characteristics (ROC) curve analysis was performed to evaluate the contribution of procalcitonin when diagnosing the onset in CCHF patients. Procalcitonin levels were measured with Diazyme latex-enhanced immunoturbidimetric method in Roche Cobas C501 analyzer. A Mann-Whitney U-test was applied to compare the groups, a Mantel-Haenszel (log-rank) test was used to calculate for graphic of original individual patient time-to-event data, and a Kaplan-Meier survival curve was plotted. Results: A ROC curve analysis identified a best predictive procalcitonin level cut-off point of 0.560 mu g/L, with a specificity of 97% and sensitivity of 27% for CCHF. The highest levels of procalcitonin were measured on day 2 during the follow-up throughout and on the 5th day peaked for a second time, lower than the first. Conclusions: Procalcitonin may serve as prognostic indicator and an auxiliary biomarker to rule out of CCHF.

Source

Turkish Journal Of Biochemistry-Turk Biyokimya Dergisi

Volume

45

Issue

5

URI

https://doi.org/10.1515/tjb-2020-0001
https://hdl.handle.net/20.500.12881/2794

Collections

  • Scopus İndeksli Yayınlar Koleksiyonu [6043]
  • WoS İndeksli Yayınlar Koleksiyonu [6088]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Policy | Guide | Contact |

DSpace@GOP

by OpenAIRE
Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeInstitution AuthorThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeInstitution Author

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Policy || Guide || Library || Tokat Gaziosmanpaşa University || OAI-PMH ||

Tokat Gaziosmanpaşa University, Tokat, Turkey
If you find any errors in content, please contact:

Creative Commons License
Tokat Gaziosmanpaşa University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@GOP:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.